Project Grant R43NS145939
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides funding of $430,957 to Neurovascular Diagnostics Inc. to develop and test a blood-based assay called AneuscreenTM. This dual-purpose assay uses gene expression analysis to predict the presence and rupture risk probability of intracranial aneurysms, a life-threatening condition. The...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $817,591 Cooperative Agreement under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program to Duke University to conduct the "Induced Suppression of Platelet Activity in Aneurysmal SAH Management-2 (ISPASM-2)" research project. The project aims to investigate the use of anti-platelet therapy to mitigate the devastating consequences of delayed cerebral ischemia,...
- This $230,925 federal Project Grant, awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders, supports a research project at Yale University to characterize central nervous system inflammation in patients with aneurysmal subarachnoid hemorrhage (ASAH). The goal is to investigate the duration of the pro-inflammatory phase after ASAH as a potential determinant of patient...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $431,750 to support a collaborative research project between Henry Ford Health and Michigan State University Health Sciences. The project aims to overexpress the CYP2C11 enzyme in peri-lesion astrocytes using an adeno-associated virus (AAV) vector, in order to increase cerebral...
- The U.S. National Institute of Neurological Disorders and Stroke (NINDS) awarded a $125,685 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Leland Stanford Junior University (Stanford University). The funding will support the development of an injectable hydrogel with an integrated urokinase plasminogen activator (uPA) motif and plasmid DNA (pDNA) platelet-derived growth factor B (PDGFB)-lipoplexes to be loaded into the...
- This federal Project Grant award of $2,353,206.00, issued by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate the role of the SPAK-NKCC1 protein complex in the choroid plexus and its contribution to blood-CSF barrier dysfunction in vascular contributions to cognitive impairment and dementia (VCID). The research aims to fill the...
- This federal Project Grant award of $770,502.00, awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to understand the molecular mechanisms by which collagen IV regulates TGF-beta signaling and its role in cerebral small vessel disease (CSVD). The research will use mouse models to perform intravital imaging of the cerebral vasculature and...
- This federal Project Grant award of $2,813,759.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant program. The award supports research to investigate the role of the noradrenergic system and its integration with glutamatergic signaling in regulating neurovascular coupling, which is the process that increases cerebral blood flow to regions of high neuronal...
- This $490,049 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research by Shearit LLC to evaluate the efficacy of their Lamiflo drug for reducing ischemic penumbra and core volumes in acute ischemic stroke. The 1-year study will test Lamiflo, a drag-reducing polymer that enhances blood flow, in rat models of middle cerebral artery...
- The National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, awarded a $314,363 project grant to Arsenal Medical, Inc. in Waltham, MA. The grant, with an award date of August 1, 2025 and a completion date of July 31, 2026, will fund the development of an engineering model of the middle meningeal artery embolization procedure for treating chronic subdural hematoma (CSDH), a...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), provides $492,110 to Aneuryst Inc. to conduct research on "Enzyme Phenotyping of Hydroxyfasudil" for the treatment of cerebral vasospasm, a leading cause of death and disability following subarachnoid hemorrhage (SAH). The research aims to establish a causal relationship between the addition of the drug fasudil, used in Japan for over three decades, and the observed improvements in cognition and functional independence compared to the only FDA-approved treatment, nimodipine. The award has an effective date of September 9, 2025 and an ultimate completion date of August 31, 2026.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $492.1k | 9/9/25 |